Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • Contact

OMRF receives $1.74 million to investigate cell death

    Home News OMRF receives $1.74 million to investigate cell death
    NextPrevious

    OMRF receives $1.74 million to investigate cell death

    By sarah | News | 0 comment | 3 January, 2017 | 0

    Copyright © 2017, The Oklahoma Publishing Co.

    An Oklahoma Medical Research Foundation scientist has received a four-year federal grant to investigate the biological process of cell death.

    Courtney Griffin/The Oklahoman

    The grant, awarded by the National Heart, Lung, and Blood Institute, will provide $1.74 million to OMRF scientist Courtney Griffin to study what triggers a form of cell death called necroptosis in the vascular system.

    The body uses programmed cell death to carry out specific biological purposes. “It’s an important and essential part of some phases of human development,” Griffin said in a news release. “For example, as embryos, our hands look like little round paddles until programmed cell death kills off the cells between our fingers.”

    This type of cell death that destroys the cells between our fingers is called apoptosis, and it has been studied for decades. However, a newer form of cell death called necroptosis has been identified recently, and Griffin is interested in identifying the causes and effects of necroptosis in blood vessels.

    While apoptosis is often seen as beneficial and orderly, necroptosis appears to be a much uglier form of cell death. In apoptosis, cells die neatly, and other cells come along to clean up behind them, Griffin said. But necroptosis results in a messy sort of cell death, which can cause inflammation and damage to nearby cells in the surrounding tissue.

    One way to compare apoptosis with necroptosis is to imagine two types of building demolition, said Griffin, who joined OMRF’s scientific staff in 2008 from the University of North Carolina at Chapel Hill.

    “Apoptosis is like an implosion, where the building’s walls fall inward onto themselves in a nice, controlled way,” she said. “But in necroptosis, it’s more like when a gas main blows and the building explodes outward. The damage is far greater and more widespread. Both buildings come down, but the resulting damage is vastly different.”

    Griffin’s lab will study the rapidly growing blood vessels in mouse embryos to investigate not only what triggers necroptosis, but also to learn about the secondary effects of the damage imposed by this form of programmed cell death.

    “Understanding the causes and effects of necroptosis on the embryonic vascular system is only the tip of the iceberg,” she said. “We hope our findings may also provide insight into how necroptosis contributes to adult vascular diseases like atherosclerosis and aneurysms.”

    The grant, 1 R01 HL134778-01, is funded through the NHLBI, a part of the National Institutes of Health.

    Source: Oklahoma Medical Research Foundation

    Read the article at newsok.com

     

     

     

     

     

    Courtney Griffin, OMRF, The Oklahoma Medical Research Foundation

    Related Posts

    • Pandemic a force of ‘positive disruption’ for telemedicine

      By sarah | 0 comment

      By Scott Meacham For this third column in my series exploring the long-term impact of the COVID pandemic on the fields of clinical research, I drew on the experience and insight Dr. Stephen M. Prescott,Read more

    • i2E investment an important validation of technology developed by OKC’s Progentec Diagnostics

      By sarah | 0 comment

      By Scott Meacham As i2E has been closing our latest round of new investments over the last few weeks, I am reminded of how in the startup world and the venture industry, investment events attractRead more

    • Prescott: A homegrown biotech success story

      By sarah | 0 comment

      By Stephen Prescott, M.D. When Novartis announced earlier this month that the U.S. Food and Drug Administration had approved the company’s new drug to treat sickle cell anemia, the press release didn’t mention Oklahoma. ButRead more

    • OKC’s Progentec Diagnostics aims to ‘radically improve’ care of lupus patients

      By sarah | 0 comment

      By Scott Meacham Lupus is chronic autoimmune condition with devastating effects. The disease is difficult to diagnose. Its course is unpredictable. There is no cure and few FDA-approved medications. Patients who have lupus live withRead more

    • When medical research turns personal

      By sarah | 0 comment

      By Scott Meacham Copyright © 2019, The Oklahoman Of the more than 120 types of brain and central nervous system tumors, Glioblastoma (also called GBM) is the most aggressive — a deadly brain cancer withRead more

    Leave a Comment

    Cancel reply

    Your email address will not be published. Required fields are marked *

    NextPrevious
    i2E-300dpi-Trans-Light
    • Events
    • News
    • Resources
    • Library
    • Love’s Cup

    Oklahoma City Office

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305
    Click HERE for printable map with directions.

    Tulsa Office

    618 E. Third Street, Suite 1
    Tulsa, OK 74120
    PHONE 918/582-5592
    Click HERE for printable map with directions.
    Copyright 2021 i2E, Inc. | All Rights Reserved
    • About i2E
    • Services
    • Investments
    • Development
      • Love’s Cup
        • Forms
        • High Growth
        • Small Business
        • Timeline
    • Portfolio 3
    • Contact
    i2E